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 1 
Introduction  2 
 3 
Atopic dermatitis (AD) results from a complex interplay of host genetic and environmental 4 
factors. There is a long established association between AD and Staphylococcus aureus. In 5 
healthy individuals this organism has a dichotomous relationship with the host, being a frequent 6 
component of the human microbiome, carried asymptomatically, and on occasion, an 7 
opportunistic pathogen capable of causing or influencing a broad ranging disease. In AD, high 8 
carriage rates of S. aureus on affected skin is commonly observed, with recent meta-analysis 9 
evidence demonstrating colonisation in approximately 70% of affected individuals 1. High 10 
frequency of carriage, and a high colonization burden, have been linked with disease severity in 11 
AD. Despite this association, relatively modest advances have been made in understanding if this 12 
is causal or consequential. With increasing numbers of microbiome studies it is becoming 13 
evident that wider cutaneous microbial imbalances, or dysbiosis, likely contribute to the 14 
observed abundance of S. aureus seen in AD, as well as the aetiology of AD. In contrast, 15 
antimicrobials, which cause dysbiosis by virtue of their activity, are still used routinely to target 16 
S. aureus in the management of this condition. Important questions remain about the extent to 17 
which microbiome composition is important in determining the ability of S. aureus to thrive and 18 
to drive disease, and the extent to which therapeutic use of antimicrobials may impact on the 19 
microbiome and the S. aureus population within it. Against a backdrop of increasing levels of 20 
antimicrobial resistance (AMR), careful stewardship of antibiotics is vital to maintain their 21 
therapeutic efficacy. In AD, this is of particular concern as S. aureus is an organism that is adept 22 
at developing AMR, and also due to the collateral damage that antibiotics inflict on the 23 
microbiome.  24 
 25 
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The concept of AD as a microbial diathesis has been a subject of detailed study over the past 26 
decade, especially with the advent of 16S rRNA sequencing as a tool to better describe the 27 
diversity of the cutaneous bacterial microbiome. Alterations in microbiome composition have 28 
been shown to vary in affected individuals compared to healthy controls. People with established 29 
AD have overall reduced cutaneous bacterial diversity in comparison to healthy individuals 2. 30 
Specific signature shifts of populations are observed to occur during disease exacerbation, 31 
mirroring increasing disease severity, with expansion of staphylococcal populations, primarily S. 32 
aureus and S. epidermidis 2. Development of AD may also be influenced by microbiome 33 
composition during infancy, with commensal staphylococci having a protective effect and being 34 
significantly less abundant in children who go on to develop AD by 12 months 3. Presently S. 35 
aureus remains the dominant organism in terms of potential contribution to AD pathogenesis. 36 
The involvement of S. aureus in disease activity is almost certainly multi-modal, through pro-37 
inflammatory interaction by adherence to keratinocytes to secretion of toxins and proteases, 38 
reviewed in detail4, and illustrated in Figure 1. At the genetic level, evidence of S. aureus strain 39 
association with AD is accumulating. Specific clones of S. aureus are more frequently isolated 40 
from diseased skin, than other more widely circulating clones in the general population. This 41 
suggests that there may be specific, clonally-associated, properties allowing it to preferentially 42 
survive on atopic skin, and drive the pathology of AD5,6.  43 
 44 
Therapeutic interventions in AD are directed at alleviating disease severity through 45 
moisturisation, resolving inflammation, and reducing bacterial burden, all of which may 46 
indirectly influence the microbiome. Emollients are the foundation of management in AD, 47 
improving epidermal barrier function, with usage reducing AD severity. Daily emollient usage in 48 
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high-risk infants may prevent the onset of AD. Recent analysis has revealed that as skin pH 49 
decreases with improved barrier function, in moisturiser treated infants, cutaneous bacterial 50 
diversity recovers, with specific higher abundance of Streptococcus salivarius in individuals who 51 
did not develop AD 7. Topical corticosteroids are hypothesised to have a similar influence, 52 
through their anti-inflammatory as well as barrier altering effects, but this remains to be properly 53 
characterised.  54 
 55 
Antimicrobials are another pillar of AD treatment, which include topical and oral antibiotics, 56 
antiseptic containing soap substitutes, and bleach baths. The precise impact they have on the AD 57 
microbiome is unclear, as they are generally used in combination with steroids and emollients, 58 
making it difficult to attribute microbiome changes to any one of these individual measures. 59 
Characterisation of cutaneous microbiota during and post treatment, both with 16S rRNA or 60 
metagenomics approaches, does not allow for resolution beyond species level, meaning 61 
variability within specific species at strain level, such as acquisition of a resistance gene, is not 62 
possible to determine. Deep sequencing of colonies isolated from skin swabs has provided a 63 
higher resolution to investigate S. aureus populations from AD patients. Within patients there is 64 
evidence of clonal expansion and diversification of the S. aureus population, and moreover, 65 
genetic adaptation to therapeutic interventions 8. These culture-based studies have also almost 66 
uniformly focused on S. aureus, therefore the impact on the remainder of the microbiota remains 67 
unresolved.  68 
 69 
Given fluctuations in S. aureus burden, which correlate with AD severity, antimicrobials are 70 
frequently used to target this pathogen. Primarily they are used as anti-staphylococcal agents, to 71 
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reduce the burden of the organism and its pro-inflammatory effect. Despite lack of robust 72 
evidence to support this practice 9, most dermatologists, allergists and other healthcare providers 73 
do so because of a perceived clinical benefit. In milder disease, more frequently seen by non-74 
specialists, antibiotic therapy has no benefit over emollients and appropriate strength topical 75 
corticosteroids 10. One potential downside in changing this practice in individuals with greater 76 
disease severity is that this patient group is at significantly higher risk of invasive S. aureus 77 
infection 11. Withholding antibiotics in people with more severe AD during disease flares with 78 
clinical evidence of infection is therefore clinically difficult to justify, and warrants study to 79 
determine if they do indeed improve clinical outcomes when used for severe flares. A 80 
confounding and critical issue in this is the lack of universally accepted definitions of 81 
colonization versus infection amongst health care providers leading to widely differing 82 
thresholds for antibiotic use and indeed overuse. 83 
 84 
Aside from the uncertain benefits of using antimicrobial agents for the management of AD it is 85 
important to consider the wider impact of these agents on S. aureus populations associated with 86 
AD. Genomic studies have illustrated the role that extensive use of antibiotics has had in 87 
generating and maintaining AMR in pathogen populations. The recent history of S. aureus as a 88 
pathogen is punctuated by the emergence and spread of AMR clones. The introduction of new 89 
antibiotics has invariably been followed shortly after by the appearance of resistant variants in 90 
clinical practice; the genetic mechanisms underpinning this resistance are summarised in Figure 91 
2. Genomic epidemiological studies have revealed how the widespread use of new antibiotics 92 
can drive the epidemic spread of emergent resistant clones 12,13. This increasing burden of 93 
resistance therefore has specific relevance to practitioners who manage AD in the 94 
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outpatient/ambulatory setting, especially those providing care for the group of patients who more 95 
frequently receive antibiotics for chronic disease management, and who therefore are at risk of 96 
the consequences of AMR. Prescribing practices in this patient group potentially select and 97 
maintenance of problematic resistance patterns.  98 
 99 
The impact of AMR on the management of AD is influenced by the prevalence of resistance in 100 
the general population. The most pertinent example is methicillin-resistant S. aureus (MRSA), 101 
where population level prevalence, particularly of community-associated MRSA (CA-MRSA), is 102 
higher in the United States compared with Northern Europe. Reported rates of MRSA in 103 
association with AD in the USA range widely from 6.8% 14 to 45%, 15 while in Europe rates are 104 
2% or lower 16,17. High prevalence of MRSA in AD drives more frequent use of broader 105 
spectrum agents, for instance clindamycin, which in turns drives higher rates of resistance.  106 
 107 
Topical antibiotics pose a particular problem in terms of resistance, outlined in Figure 3. They 108 
are more widely used and are applied with a range of adherence to correct application 109 
recommendations, often with sub-therapeutic dosing. These factors likely drive rapid generation 110 
of resistance in treated individuals. In Europe, usage of topical fusidic acid (FA) has led to 111 
problematic rates of resistance specifically in dermatology, with rates of 40% or more are 112 
commonly reported in AD patients, and specific mechanisms of resistance in this population 16,17.  113 
In contrast, FA susceptibility is almost uniform in the USA where the agent is not used. 114 
Mupirocin resistance (MupR), conversely, is more prevalent in countries with higher MRSA 115 
prevalence. Reported rates from the USA in dermatology patients range from 1.8% to 31.3%, 116 
with AD a disease-specific risk factor for carriage of MupR S. aureus 18. Studies from across 117 
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Europe, where the agent is generally reserved for MRSA decolonisation therapy, report much 118 
lower ranges of MupR associated with AD between 0.7% and 4% 16,19.  119 
 120 
Prevalence aside, there is evidence to suggest that MRSA may be associated with greater disease 121 
severity. Altered toxin secretion profiles of CA-MRSA strains is one mechanism that has been 122 
proposed as an explanation for this 20. MRSA has a greater effect on displacing cutaneous 123 
diversity than methicillin-sensitive S. aureus (MSSA) during AD flares14. MRSA has specific 124 
effects on corynebacterial and streptococcal species and not on Staphylococcus epidermidis, 125 
another staphylococcal component of the skin microbiome. However, overall MRSA 126 
colonisation did not correlate with overall disease severity.14 These are interesting observations, 127 
and both the aforementioned studies demonstrate the potential for lineage-specific properties of 128 
S. aureus having differing effects on the skin in AD. Methicillin resistance is restricted within 129 
specific lineages, meaning that the observed variable biological impact does not necessarily 130 
relate to resistance profile and is perhaps more reflective of the general biological properties of 131 
the MRSA clones.  132 
 133 
Even when directly targeted, antimicrobial therapy will still have off-target effects both on the 134 
organism as well as the rest of the cutaneous microflora. This is exemplified by observations 135 
from New Zealand, which has one of the world’s highest rates of usage of topical antibiotics. In 136 
this setting, combined genomic and epidemiological evidence has shown that usage of mupirocin 137 
and FA, largely for minor skin infections, led to the selection and success of a multi-drug 138 
resistant sequence type (ST) 1 S. aureus clone in the country 21. The authors of this study also 139 
demonstrate that in vitro exposure to these agents co-selected for strains carrying completely 140 
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unrelated AMR determinants. When considering the wider impact of AMR selection and AD, it 141 
is worth reflecting on S. epidermidis, which is carried almost universally as a commensal and 142 
which may have modulating effects on AD development or severity and on SA carriage. 143 
Antimicrobial usage in general population terms has led to the emergence of multi-drug resistant 144 
clones of S. epidermidis globally, worryingly harbouring resistance to last-line glycopeptide 145 
antibiotics as well as topical agents such as FA 22. These examples illustrate that prescribing in 146 
AD has the potential to influence wider populations of S. aureus but also the effect that 147 
antibiotics may have on other commensals when used in AD.  148 
 149 
As a final point for consideration, AMR generated by classes of antibiotics used to treat AD can 150 
also directly influence virulence. Mupriocin resistance, conferred by a point mutation in the ileS 151 
gene, significantly reduces the production of phenol soluble modulins by S. aureus, including α 152 
and δ toxins 23. This finding holds specific relevance as these toxins have been directly 153 
mechanistically linked to AD skin inflammation; meaning AMR may have pleiotropic effects on 154 
microbial association with the disease. 155 
 156 
Looking to the future there is an urgent need to consider the impact that antimicrobials have on 157 
S. aureus and the wider cutaneous microbiota when used in AD. These interventions will 158 
doubtless have broader ranging consequences than we currently understand. With the emerging 159 
problem of AMR there is a need to be more critical of existing practice, and an imperative need 160 
for high quality clinical evidence to support such widespread antimicrobial interventions. There 161 
is also a need for targeted functional research to define the precise role S. aureus plays in AD to 162 
justify and precisely target anti-staphylococcal treatment. With dwindling antimicrobial reserves, 163 
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harnessing the potential therapeutic benefits of naturally occurring cutaneous antimicrobial 164 
peptides is an interesting prospective approach on the horizon 24, which may provide us a route 165 
to circumvent the well-recognised  problems with using broad-spectrum antibiotics in AD.  166 
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Figure Legends 
 
Figure 1:  Postulated mechanisms by which Staphylococcus aureus contributes to the pathophysiology 
of atopic dermatitis. 
 
Figure 2:  S. aureus resistance mechanisms 
 
Figure 3:  S. aureus colonizing AD affected skin 
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